Journal
NEUROSURGERY CLINICS OF NORTH AMERICA
Volume 30, Issue 2, Pages 219-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2018.12.005
Keywords
Epilepsy; Seizures; Epilepsy surgery; Neuromodulation; Vagus nerve stimulator
Categories
Funding
- NIH-NINDS [R00NS097618, F31NS106735]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS106735] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Vagus nerve stimulation (VNS) was the first neuromodulation device approved for treatment of epilepsy. In more than 20 years of study, VNS has consistently demonstrated efficacy in treating epilepsy. After 2 years, approximately 50% of patients experience at least 50% reduced seizure frequency. Adverse events with VNS treatment are rare and include surgical adverse events (including infection, vocal cord paresis, and so forth) and stimulation side effects (hoarseness, voice change, and cough). Future developments in VNS, including closed-loop and noninvasive stimulation, may reduce side effects or increase efficacy of VNS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
